Concord Biotech Limited (CONCORDBIO) — Cash Flow Quality Index
Concord Biotech Limited (CONCORDBIO) has a Cash Flow Quality Index of 0.67x as of March 2025. Operating cash flow of Rs2.47 Billion is below net income of Rs3.72 Billion, suggesting accrual-heavy earnings not yet converted to cash. Also explore CONCORDBIO total asset value for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Concord Biotech Limited Cash Flow Quality Index (2020–2025)
Historical Cash Flow Quality Index for Concord Biotech Limited across 6 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check CONCORDBIO tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Concord Biotech Limited (2020–2025)
Year-by-year earnings quality comparison for Concord Biotech Limited. For live market cap and the full company financial profile, see Concord Biotech Limited market capitalisation.
| Year | Quality Index | Operating CF (INR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.67x | Rs2.47 Billion | Rs3.72 Billion | ▼ -22.7% |
| 2024 | 0.86x | Rs2.65 Billion | Rs3.08 Billion | ▼ -15.9% |
| 2023 | 1.02x | Rs2.46 Billion | Rs2.40 Billion | ▼ -13.6% |
| 2022 | 1.19x | Rs2.07 Billion | Rs1.75 Billion | ▲ +67.0% |
| 2021 | 0.71x | Rs1.67 Billion | Rs2.35 Billion | ▼ -22.4% |
| 2020 | 0.92x | Rs1.55 Billion | Rs1.69 Billion | — |